Pulmonary delivered Nanofitins® to treat respiratory indications locally
The strategy relies on a dual targeting: direct administration to the targeted organ and targeting the right cells or effectors. Nanofitins being 20 times smaller than antibodies, highly soluble and extremely stable proteins, they can be easily nebulized. Affilogic already demonstrated bio-distribution of Nanofitins into different compartments of the lungs and in vivo efficacy in the lungs in animal models.
Affilogic is developing a platform for pulmonary delivery of Nanofitin-based biotherapeutics with a local activity in the lungs, which will initially be validated in the context of a viral infection with lung conditions, COVID-19.
Nanofitins® targeting multiple epitopes of a virus reduce infection in mice lungs
Nanofitins can easily be assembled with each other by a simple genetic fusion, to form cooperative treatments against multiple targets in a single compound. This property has been validated in particular in the Nanomodule project, a “100% Nanofitins” assembly to treat cancer, by assembling Nanofitins to reach the tumour and Nanofitins representing the “active principles” to fight the tumor, and which was supported by the European Regional Development Fund (ERDF / FEDER) via the Region Pays de Loire (PL0015680).
The Respitude project supports the development of a candidate Nanofitin simultaneously targeting multiple epitopes of the SARS-Cov2 S surface protein, neutralizing its interaction with cells. The financial support received from the French Government in the framework of France Relance (May 2021 to April2024) shall enable preclinical and clinical development (phase I) of such therapeutic candidate, including efficacy validation and safety profile.
The PulmoVia project focuses on the route of administration and shall validate a formulation for pulmonary delivery of anti-SARS-Cov2 Nanofitins (nebulization, inhalation…) as well as confirming the platform on Nanofitins in other pulmonary diseases. This is particularly interesting for external attacks on the lungs, such as viral infections (RSV) or bacterial infections (antibiotic-resistant pathogens such as Pseudomonas aeruginosa). If we also consider diseases such as lung cancers or pulmonary fibrosis , medical needs are very broad and in high demand. This project is partially sponsored from May 2021 to April 2023 by a grant from the European Regional Development Fund(ERDF / FEDER) via the Region Pays de Loire (PL0031807), in the framework of «React EU » – the European Union addressing the COVID-19 pandemic.